| Anna M Cook, PMHNP, CNS, MSN | |
|
163 W Univeristy Parkway, Jackson, TN 38305 | |
| (731) 363-5584 | |
| Not Available |
| Full Name | Anna M Cook |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 163 W Univeristy Parkway, Jackson, Tennessee |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063721314 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2200X | Clinical Nurse Specialist - Adult Health | 15203 (Tennessee) | Secondary |
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | 15203 (Tennessee) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Imind Geriatrics And Behavioral Health Llc | 2163800368 | 2 |
| Imind Mental Health And Wellness Llc | 8426307364 | 3 |
News Archive
In the wake of multiple state bans on caffeinated alcoholic beverages (CABs) and an FDA warning to four companies to remove their products from the marketplace, an article published online today in the American Journal of Preventive Medicine delineates the scope of the public health problem and suggests areas of research that might help address it.
Cardiovascular Systems, Inc. (CSI), has received Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to evaluate the safety and effectiveness of its Diamondback 360® System in the treatment of calcified coronary lesions. With this conditional approval, CSI is authorized to begin its pivotal trial, ORBIT II, in early 2010 and initially enroll up to 100 patients at as many as 50 U.S. sites.
When an organism is exposed to life-threatening conditions, it sounds the alarm and a cellular emergency program, the heat shock response, is initiated.
CMU's Jeffrey O. Hollinger, director of the center, and Professor Krzysztof Matyjaszewski have received a three-year, $2.9 million U.S. Department of Defense research grant to develop a therapy that would aid amputees, specifically wounded soldiers. The therapy aims to prevent bone nodules from forming in the muscle at the site of amputation, a painful condition that makes it difficult for amputees to wear limb prostheses.
› Verified 5 days ago
| Entity Name | Southeastern Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083835441 PECOS PAC ID: 0042307852 Enrollment ID: O20071025000571 |
News Archive
In the wake of multiple state bans on caffeinated alcoholic beverages (CABs) and an FDA warning to four companies to remove their products from the marketplace, an article published online today in the American Journal of Preventive Medicine delineates the scope of the public health problem and suggests areas of research that might help address it.
Cardiovascular Systems, Inc. (CSI), has received Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to evaluate the safety and effectiveness of its Diamondback 360® System in the treatment of calcified coronary lesions. With this conditional approval, CSI is authorized to begin its pivotal trial, ORBIT II, in early 2010 and initially enroll up to 100 patients at as many as 50 U.S. sites.
When an organism is exposed to life-threatening conditions, it sounds the alarm and a cellular emergency program, the heat shock response, is initiated.
CMU's Jeffrey O. Hollinger, director of the center, and Professor Krzysztof Matyjaszewski have received a three-year, $2.9 million U.S. Department of Defense research grant to develop a therapy that would aid amputees, specifically wounded soldiers. The therapy aims to prevent bone nodules from forming in the muscle at the site of amputation, a painful condition that makes it difficult for amputees to wear limb prostheses.
› Verified 5 days ago
| Entity Name | Support Solutions Of The Mid-south |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407025539 PECOS PAC ID: 0446418834 Enrollment ID: O20120214000467 |
News Archive
In the wake of multiple state bans on caffeinated alcoholic beverages (CABs) and an FDA warning to four companies to remove their products from the marketplace, an article published online today in the American Journal of Preventive Medicine delineates the scope of the public health problem and suggests areas of research that might help address it.
Cardiovascular Systems, Inc. (CSI), has received Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to evaluate the safety and effectiveness of its Diamondback 360® System in the treatment of calcified coronary lesions. With this conditional approval, CSI is authorized to begin its pivotal trial, ORBIT II, in early 2010 and initially enroll up to 100 patients at as many as 50 U.S. sites.
When an organism is exposed to life-threatening conditions, it sounds the alarm and a cellular emergency program, the heat shock response, is initiated.
CMU's Jeffrey O. Hollinger, director of the center, and Professor Krzysztof Matyjaszewski have received a three-year, $2.9 million U.S. Department of Defense research grant to develop a therapy that would aid amputees, specifically wounded soldiers. The therapy aims to prevent bone nodules from forming in the muscle at the site of amputation, a painful condition that makes it difficult for amputees to wear limb prostheses.
› Verified 5 days ago
| Entity Name | Imind Mental Health And Wellness Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144714882 PECOS PAC ID: 8426307364 Enrollment ID: O20180825000103 |
News Archive
In the wake of multiple state bans on caffeinated alcoholic beverages (CABs) and an FDA warning to four companies to remove their products from the marketplace, an article published online today in the American Journal of Preventive Medicine delineates the scope of the public health problem and suggests areas of research that might help address it.
Cardiovascular Systems, Inc. (CSI), has received Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to evaluate the safety and effectiveness of its Diamondback 360® System in the treatment of calcified coronary lesions. With this conditional approval, CSI is authorized to begin its pivotal trial, ORBIT II, in early 2010 and initially enroll up to 100 patients at as many as 50 U.S. sites.
When an organism is exposed to life-threatening conditions, it sounds the alarm and a cellular emergency program, the heat shock response, is initiated.
CMU's Jeffrey O. Hollinger, director of the center, and Professor Krzysztof Matyjaszewski have received a three-year, $2.9 million U.S. Department of Defense research grant to develop a therapy that would aid amputees, specifically wounded soldiers. The therapy aims to prevent bone nodules from forming in the muscle at the site of amputation, a painful condition that makes it difficult for amputees to wear limb prostheses.
› Verified 5 days ago
| Entity Name | Imind Geriatrics And Behavioral Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265174775 PECOS PAC ID: 2163800368 Enrollment ID: O20220531001450 |
News Archive
In the wake of multiple state bans on caffeinated alcoholic beverages (CABs) and an FDA warning to four companies to remove their products from the marketplace, an article published online today in the American Journal of Preventive Medicine delineates the scope of the public health problem and suggests areas of research that might help address it.
Cardiovascular Systems, Inc. (CSI), has received Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to evaluate the safety and effectiveness of its Diamondback 360® System in the treatment of calcified coronary lesions. With this conditional approval, CSI is authorized to begin its pivotal trial, ORBIT II, in early 2010 and initially enroll up to 100 patients at as many as 50 U.S. sites.
When an organism is exposed to life-threatening conditions, it sounds the alarm and a cellular emergency program, the heat shock response, is initiated.
CMU's Jeffrey O. Hollinger, director of the center, and Professor Krzysztof Matyjaszewski have received a three-year, $2.9 million U.S. Department of Defense research grant to develop a therapy that would aid amputees, specifically wounded soldiers. The therapy aims to prevent bone nodules from forming in the muscle at the site of amputation, a painful condition that makes it difficult for amputees to wear limb prostheses.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anna M Cook, PMHNP, CNS, MSN 253 Flagstone Dr, Jackson, TN 38305-8583 Ph: (731) 300-0810 | Anna M Cook, PMHNP, CNS, MSN 163 W Univeristy Parkway, Jackson, TN 38305 Ph: (731) 363-5584 |
News Archive
In the wake of multiple state bans on caffeinated alcoholic beverages (CABs) and an FDA warning to four companies to remove their products from the marketplace, an article published online today in the American Journal of Preventive Medicine delineates the scope of the public health problem and suggests areas of research that might help address it.
Cardiovascular Systems, Inc. (CSI), has received Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to evaluate the safety and effectiveness of its Diamondback 360® System in the treatment of calcified coronary lesions. With this conditional approval, CSI is authorized to begin its pivotal trial, ORBIT II, in early 2010 and initially enroll up to 100 patients at as many as 50 U.S. sites.
When an organism is exposed to life-threatening conditions, it sounds the alarm and a cellular emergency program, the heat shock response, is initiated.
CMU's Jeffrey O. Hollinger, director of the center, and Professor Krzysztof Matyjaszewski have received a three-year, $2.9 million U.S. Department of Defense research grant to develop a therapy that would aid amputees, specifically wounded soldiers. The therapy aims to prevent bone nodules from forming in the muscle at the site of amputation, a painful condition that makes it difficult for amputees to wear limb prostheses.
› Verified 5 days ago
Katherine E Wyatt, A.P.R.N. Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 145 Innovation Dr, Jackson, TN 38305 Phone: 731-422-0213 Fax: 731-660-8301 | |
Amy K Lawrence, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2863 Highway 45 Byp, Jackson, TN 38305 Phone: 731-422-0213 Fax: 731-660-8380 | |
Lauren Williams, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1047 Union University Dr, Jackson, TN 38305 Phone: 731-256-0035 | |
Anna K Younger, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 145 Innovation Dr, Jackson, TN 38305 Phone: 731-422-0213 Fax: 731-660-8301 | |
Kirsten Siler, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 27a Medical Center Drive, Jackson, TN 38301 Phone: 731-541-3310 | |
Stephanie Pool, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 36 Pemberton Cv, Jackson, TN 38305 Phone: 731-394-1145 Fax: 844-374-0233 | |
Kimberlie A Simpson, APRN, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 23 Independence Ln, Jackson, TN 38305 Phone: 731-617-1483 |